Addition of Hypofractionated High Dose Radiation in Oligometastatic Disease
Status:
Not yet recruiting
Trial end date:
2027-12-01
Target enrollment:
Participant gender:
Summary
This is a 2:1 randomized multicentre open label phase III study of radiation combined with
standard systemic treatment compared with systemic treatment alone in oligometastatic (≤5
metastases) NSCLC. Stratification factors: performance status, gender and systemic strategy.
The systemic treatment consists of chemotherapy/chemoimmunotherapy or immunotherapy and is
given according to local practice. During the first 3 months of systemic treatment, aiming to
start around the 2nd cycle is radiotherapy delivered to all known lesions. Preferably with
SBRT /SRT/SRS but conventional radiotherapy may also be used. After the first three cycles of
systemic treatment, the patients are assessed, and after four cycles, they are continuing
maintenance therapy if indicated. The patients are followed with radiology every three
months.